[Hepatitis C virus-associated glomerulonephritis].
Yamabe
Hideaki
H
Hirosaki University School of Health Sciences.
D000936:Antigen-Antibody Complex / Q000276:immunology; D000998:Antiviral Agents / Q000627:therapeutic use; D003449:Cryoglobulinemia / Q000276:immunology / Q000821:virology; D004359:Drug Therapy, Combination; D015432:Glomerulonephritis, Membranoproliferative / Q000453:epidemiology / Q000473:pathology / Q000628:therapy / Q000821:virology*; D016174:Hepacivirus / Q000276:immunology*; D006526:Hepatitis C / Q000821:virology*; D018937:Hepatitis C Antibodies / Q000276:immunology; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology / Q000378:metabolism; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D007668:Kidney / Q000378:metabolism / Q000473:pathology; D010951:Plasma Exchange; D011379:Prognosis
D000936:Antigen-Antibody Complex; D000998:Antiviral Agents; D018937:Hepatitis C Antibodies; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; C043325:cryoglobulin M; D007372:Interferons